Literature DB >> 8381710

Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study.

F J Major1, J A Blessing, S G Silverberg, C P Morrow, W T Creasman, J L Currie, E Yordan, M F Brady.   

Abstract

BACKGROUND: A clinicopathologic evaluation of clinical Stage I and II uterine sarcoma was done by the Gynecologic Oncology Group from 1979-1988.
METHODS: After all eligibility criteria were met, 453 cases were evaluable and analyzed for prognostic factors.
RESULTS: Of the 301 mixed mesodermal tumors (MMT), 167 were homologous (HO), and 134 were heterologous (HE). Fifty-nine tumors were leiomyosarcomas (LM). The remaining 93 sarcomas were predominantly stromal cell and adenosarcomas. For this study, only the MMT or LM tumors were analyzed. The recurrence rate for all MMT was 53% (HO, 44%; HE, 63%). The recurrence rate for LM was 71%. The site of the first recurrence included the pelvis in 21% of MMT and 14% in LM. Factors significantly related to progression-free interval (PFI) by univariate analysis among MMT were adnexal spread, lymph node metastases, tumor size, lymphatic-vascular space involvement, histologic grade, cell type, age, peritoneal cytologic findings, and depth of uterine tumor site of invasion. The prognostic factors based on multivariate analysis were adnexal spread, lymph node metastases, histologic cell type (HO versus HE), and grade of sarcoma. For LM, the mitotic index was the only factor significantly related to PFI.

Entities:  

Mesh:

Year:  1993        PMID: 8381710     DOI: 10.1002/cncr.2820710440

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  115 in total

1.  A rare case of uterine leiomyosarcoma: a case report.

Authors:  Venkata Sujatha Vellanki; Meghana Rao; Chinna Babu Sunkavalli; Rao N Chinamotu; Shailaja Kaja
Journal:  J Med Case Rep       Date:  2010-07-22

2.  Successful removal of uterine leiomyosarcoma tumour thrombus propagating to the right atrium.

Authors:  Yu Hui Lim; Lui Shiong Lee; Chong Hee Lim; Ghee Kheng Chew
Journal:  BMJ Case Rep       Date:  2015-11-25

Review 3.  A review of treatment of uterine leiomyosarcomas.

Authors:  Nicholas Reed
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

4.  A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study.

Authors:  Linda R Duska; John A Blessing; Jacob Rotmensch; Robert S Mannel; Parviz Hanjani; Peter G Rose; Don S Dizon
Journal:  Gynecol Oncol       Date:  2014-08-01       Impact factor: 5.482

Review 5.  Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.

Authors:  Khadra Galaal; Esther van der Heijden; Keith Godfrey; Raj Naik; Ali Kucukmetin; Andrew Bryant; Nagindra Das; Alberto D Lopes
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

6.  [Uterine sarcoma treatment].

Authors:  G Köhler
Journal:  Pathologe       Date:  2009-07       Impact factor: 1.011

7.  A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.

Authors:  Aaron H Wolfson; Mark F Brady; Thomas Rocereto; Robert S Mannel; Yi-Chun Lee; Robert J Futoran; David E Cohn; Olga B Ioffe
Journal:  Gynecol Oncol       Date:  2007-09-05       Impact factor: 5.482

8.  18F-fluorodeoxyglucose positron emission tomography in uterine carcinosarcoma.

Authors:  Kung-Chu Ho; Chyong-Huey Lai; Tzu-I Wu; Koon-Kwan Ng; Tzu-Chen Yen; Gigin Lin; Ting-Chang Chang; Chun-Chieh Wang; Swei Hsueh; Huei-Jean Huang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-19       Impact factor: 9.236

9.  Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors.

Authors:  Roisin O'Cearbhaill; Qin Zhou; Alexia Iasonos; Robert A Soslow; Mario M Leitao; Carol Aghajanian; Martee L Hensley
Journal:  Gynecol Oncol       Date:  2009-11-24       Impact factor: 5.482

Review 10.  Treatment of early uterine sarcomas: disentangling adjuvant modalities.

Authors:  Flora Zagouri; Athanasios-Meletios Dimopoulos; Stelios Fotiou; Vassilios Kouloulias; Christos A Papadimitriou
Journal:  World J Surg Oncol       Date:  2009-04-08       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.